| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics, Inc. (SRPT) has 14 insiders with recent SEC Form 4 filings, including 2 buys and 12 sells. SRPT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.98M | $52.66M | - | |
| CEO | 490.3K | $8.65M | - | |
| Pres | 227.2K | $4.01M | - | |
| Dir | 214.4K | $3.78M | - | |
| COO | 202.0K | $3.56M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2018 | Barry Richard70 | Director | Sell | 75,000 | $130.34 | $9,775,500.00 | -2.3% | |
| Nov 30, 2017 | Wigzell Hans Lennart Rudolf60 | Director | Sale+OE | 6,667 | $55.89 | $372,618.63 | -50.0% | |
| Nov 8, 2017 | Ingram Douglas S | President &CEO | Buy | 38,138 | $52.44 | $1,999,956.72 | +10.0% | |
| Nov 6, 2017 | Ruff Shamim | SVP, Regulatory Affairs &Qual | Sale+OE | 10,000 | $55.00 | $550,000.00 | -27.0% | |
| Oct 3, 2017 | Ruff Shamim | SVP, Regulatory Affairs &Qual | Sale+OE | 11,500 | $50.00 | $575,000.00 | -29.8% | |
| Jul 27, 2017 | Ingram Douglas S | President &CEO | Buy | 47,058 | $42.50 | $1,999,965.00 | +14.0% | |
| Jul 21, 2017 | Ruff Shamim | SVP, Regulatory Affairs &Qual | Sale+OE | 12,138 | $42.97 | $521,572.00 | -16.1% | |
| Jul 20, 2017 | Kaye Edward M. Md46 | Director | Sell | 10,000 | $41.00 | $410,000.00 | -16.0% | |
| Jul 20, 2017 | Howton David T | SVP, General Counsel | Sale+OE | 25,000 | $41.00 | $1,025,000.00 | -35.9% | |
| Jul 20, 2017 | Cumbo Alexander | SVP, Chief Commercial Officer | Sale+OE | 5,918 | $41.00 | $242,638.00 | -13.7% |